Donald Bergstrom
Patrimonio netto: 6 M $ in data 31/05/2026
Patrimonio netto: 6 M $ in data 31/05/2026
Donald A. Bergstrom is currently an Independent Director at Cellectis SA since 2022, a Director at Cellectis, Inc., and President-Research & Development at Relay Therapeutics, Inc. since 2018.
Formerly, Dr. Bergstrom was an Independent Director at Fusion Pharmaceuticals, Inc. from 2021 to 2024, Chief Medical Officer & Senior Vice President at Mersana Therapeutics, Inc. from 2014 to 2018, Global Head-Translational & Experimental Medicine at Sanofi-Aventis U.S.
LLC from 2010 to 2014, Principal at Merck Research Laboratories Massachusetts LLC, and Global Head-Translational Medicine at Genzyme Therapeutics Ltd. from 2010 to 2014.
Education includes a doctorate from the University of Washington and an undergraduate degree from The Johns Hopkins University.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 28/04/2026 | 418.557 ( 0,22% ) | 6 M $ | 31/05/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| RELAY THERAPEUTICS, INC. | Direttore Tecnico/Scientifico/R&S | 01/04/2018 |
| CELLECTIS S.A. | Direttore/Membro del Consiglio | 28/06/2022 |
Cellectis, Inc.
Cellectis, Inc. Pharmaceuticals: MajorHealth Technology Engages in the upstream research of genome engineering and in the development of pre-engineered products for pharmaceutical industry, cell therapies, seed companies, and laboratory researchers | Direttore/Membro del Consiglio | - |
| Società | Posizione | Fine |
|---|---|---|
| FUSN PHAR | Direttore/Membro del Consiglio | 04/06/2024 |
| MERSANA THERAPEUTICS | Direttore Tecnico/Scientifico/R&S | 31/03/2018 |
Sanofi-Aventis U.S. LLC
Sanofi-Aventis U.S. LLC Pharmaceuticals: MajorHealth Technology Develops medicines, vaccines and provides specialized healthcare & clinical trail services | Corporate Officer/Principal | 01/01/2014 |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops transformative therapies for patients affected by rare and debilitating diseases | Corporate Officer/Principal | 01/01/2014 |
Merck Research Laboratories Massachusetts LLC
Merck Research Laboratories Massachusetts LLC Pharmaceuticals: MajorHealth Technology Discovers, develops, and markets a broad range of human and animal health products | Corporate Officer/Principal | - |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 10 |
|---|---|
Mersana Therapeutics, Inc.
Mersana Therapeutics, Inc. BiotechnologyHealth Technology Develops and manufactures antibody drug conjugates to improve patient outcomes in multiple oncology indications | Health Technology |
University of Washington
University of Washington Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Johns Hopkins University
The Johns Hopkins University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cellectis SA
Cellectis SA Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops immunotherapies | Health Technology |
Sanofi-Aventis U.S. LLC
Sanofi-Aventis U.S. LLC Pharmaceuticals: MajorHealth Technology Develops medicines, vaccines and provides specialized healthcare & clinical trail services | Health Technology |
Merck Research Laboratories Massachusetts LLC
Merck Research Laboratories Massachusetts LLC Pharmaceuticals: MajorHealth Technology Discovers, develops, and markets a broad range of human and animal health products | Health Technology |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops transformative therapies for patients affected by rare and debilitating diseases | Health Technology |
Cellectis, Inc.
Cellectis, Inc. Pharmaceuticals: MajorHealth Technology Engages in the upstream research of genome engineering and in the development of pre-engineered products for pharmaceutical industry, cell therapies, seed companies, and laboratory researchers | Health Technology |
Relay Therapeutics, Inc.
Relay Therapeutics, Inc. BiotechnologyHealth Technology Operates as clinical-stage precision medicine company, which focus on enhancing small molecule therapeutic discovery in targeted oncology | Health Technology |
Fusion Pharmaceuticals, Inc.
Fusion Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company developing next-generation radiopharmaceuticals for the treatment of cancer | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale